ASND - Ascendis Pharma A/S
| Previous Close | 139.90 |
| Open | 140.33 |
| Bid | 133.60 x 1100 |
| Ask | 133.83 x 1200 |
| Day's Range | 132.95 - 140.33 |
| 52 Week Range | 66.11 - 142.94 |
| Volume | 159,340 |
| Avg. Volume | 256,493 |
| Market Cap | 6.378B |
| Beta (5Y Monthly) | 0.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.87 |
| Earnings Date | Nov 17, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 158.39 |
- Simply Wall St.
Shareholders Are Raving About How The Ascendis Pharma (NASDAQ:ASND) Share Price Increased 554%
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...
- GlobeNewswire
Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant unmet medical needs, will provide an outlook for 2020 and review progress towards Vision 3x3, the company’s strategic roadmap through 2025 to achieve sustainable growth at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. For our endocrinology rare disease portfolio, we were successful in our first phase 3 trial for a TransCon product candidate, TransCon hGH, and we advanced two other programs globally into phase 2.
- GlobeNewswire
Ascendis Pharma A/S Announces Participation in 38th Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, Jan. 09, 2020 -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet.
- Insider Monkey
How Did Ascendis Pharma A/S (ASND) Compare Against Hedge Fund Darlings in 2019?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
- Thomson Reuters StreetEvents
Edited Transcript of ASND earnings conference call or presentation 18-Nov-19 9:30pm GMT
Q3 2019 Ascendis Pharma A/S Earnings Call
- Insider Monkey
Here’s What Hedge Funds Think About Ascendis Pharma A/S (ASND)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- Simply Wall St.
Ascendis Pharma A/S Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
Last week saw the newest third-quarter earnings release from Ascendis Pharma A/S (NASDAQ:ASND), an important milestone...
- Zacks
Top Ranked Momentum Stocks to Buy for November 21st
Top Ranked Momentum Stocks to Buy for November 21st
- GlobeNewswire
Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results
– Continued execution of global endocrinology rare disease programs as planned regulatory filings for TransCon™ hGH in 2020 advance on track – – Expanded PaTH Forward Trial.
- Zacks
Top Ranked Momentum Stocks to Buy for November 18th
Top Ranked Momentum Stocks to Buy for November 18th
- GlobeNewswire
Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United States
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address unmet medical needs, today announced a protocol addendum designed to facilitate enrollment of subjects previously treated with NATPARA (parathyroid hormone) for Injection in the United States (US) in PaTH Forward, a global phase 2 trial evaluating the safety, tolerability and efficacy of TransCon PTH in adult subjects with hypoparathyroidism (HP). TransCon PTH is an investigational long-acting prodrug of parathyroid hormone (PTH) in development as a potential once-daily replacement therapy for HP.
- Zacks
What's in Store for Helmerich & Payne (HP) in Q4 Earnings?
Helmerich & Payne's (HP) much popular technologically-advanced FlexRigs with strong daily rate margins might reflect on segmental profits in the to-be-reported results.
- Zacks
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.
- GlobeNewswire
Ascendis Pharma A/S Announces Upcoming Investor Presentation in November
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate in the Stifel 2019 Healthcare Conference in November. A live webcast will be available in the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.
- GlobeNewswire
Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the presentation of preclinical data for TransCon Toll-like Receptor (TLR) 7/8 Agonist, an oncology product candidate designed to provide sustained local release of resiquimod, a small molecule with immune-activating and anti-tumor properties, at the Society for Immunotherapy of Cancer (SITC) annual meeting in National Harbor, Maryland. The poster will be presented on Saturday, November 9, 2019.
- Zacks
CannTrust (CTST) to Report Q3 Earnings: What's in Store?
On CannTrust's (CTST) third-quarter earnings call, investor focus will be on the company's efforts to regain licenses for producing and selling cannabis.
- Zacks
Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?
Zoetis (ZTS) is expected to provide pipeline updates during the third-quarter earnings call.
- GlobeNewswire
Ascendis Pharma A/S Announces Third Quarter 2019 Financial Results and Business Update Conference Call on November 18
COPENHAGEN, Denmark, Nov. 04, 2019 -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet.
- Zacks
Ascendis Pharma A/S (ASND) Upgraded to Buy: Here's Why
Ascendis Pharma A/S (ASND) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- GlobeNewswire
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ hGH for the Treatment of Pediatric Growth Hormone Deficiency in Europe
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced the European Commission (EC) has granted Orphan Designation to TransCon Growth Hormone (hGH), a long-acting growth hormone therapy in development as a once-weekly treatment for pediatric growth hormone deficiency. TransCon hGH is designed to provide sustained release of unmodified growth hormone, the same growth hormone used in daily therapies, at a predictable rate over one week.
- Thomson Reuters StreetEvents
Edited Transcript of ASND earnings conference call or presentation 28-Aug-19 8:30pm GMT
Q2 2019 Ascendis Pharma A/S Earnings Call
- GlobeNewswire
Ascendis Pharma A/S Announces Upcoming Investor Presentation in October
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate at the 2019 Cantor Global Healthcare Conference in October. A live webcast will be available in the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.
